Serveur d'exploration MERS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

The synthesis and biological activities of oligodeoxynucleotides that are covalently linked to psoralen at their 5' ends.

Identifieur interne : 002793 ( PubMed/Corpus ); précédent : 002792; suivant : 002794

The synthesis and biological activities of oligodeoxynucleotides that are covalently linked to psoralen at their 5' ends.

Auteurs : L X Wang ; D C Yang ; Y Y Lu ; Y. Takagi ; K. Taira ; T. Li ; L H Zhang

Source :

RBID : pubmed:8872455

English descriptors

Abstract

Four oligodeoxynucleotides (15-mers), designated 13 through 16, and the corresponding conjugates, designated 17 through 20, in which psoralen was covalently linked to the 5' end of each oligonucleotide were synthesized. Compounds 16 and 20 contained a sequence that was complementary to part of the first four codons and the upstream sequence close to the ribosome-binding site of c-Ha-ras mRNA. Compounds 16 and 20 inhibited the growth of cells that had been transformed by the c-Ha-ras plasmid, with accompanying suppression of the expression of the activated c-Ha-ras oncogene. The antisense oligonucleotides 16 and 20 also appeared to cause partial reversion of the major phenotypic characteristics of transformed cells, which included inhibition of anchorage-independent growth. Compound 20, which contained psoralen, was a more efficient inhibitor of the growth of transformed cells than compound 16 without psoralen, a result that suggests psoralen might have increased the ability of the oligodeoxynucleotides to enter the cells.

PubMed: 8872455

Links to Exploration step

pubmed:8872455

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">The synthesis and biological activities of oligodeoxynucleotides that are covalently linked to psoralen at their 5' ends.</title>
<author>
<name sortKey="Wang, L X" sort="Wang, L X" uniqKey="Wang L" first="L X" last="Wang">L X Wang</name>
<affiliation>
<nlm:affiliation>School of Pharmaceutical Sciences, Beijing Medical University, People's Republic of China.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Yang, D C" sort="Yang, D C" uniqKey="Yang D" first="D C" last="Yang">D C Yang</name>
</author>
<author>
<name sortKey="Lu, Y Y" sort="Lu, Y Y" uniqKey="Lu Y" first="Y Y" last="Lu">Y Y Lu</name>
</author>
<author>
<name sortKey="Takagi, Y" sort="Takagi, Y" uniqKey="Takagi Y" first="Y" last="Takagi">Y. Takagi</name>
</author>
<author>
<name sortKey="Taira, K" sort="Taira, K" uniqKey="Taira K" first="K" last="Taira">K. Taira</name>
</author>
<author>
<name sortKey="Li, T" sort="Li, T" uniqKey="Li T" first="T" last="Li">T. Li</name>
</author>
<author>
<name sortKey="Zhang, L H" sort="Zhang, L H" uniqKey="Zhang L" first="L H" last="Zhang">L H Zhang</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="1995">1995</date>
<idno type="RBID">pubmed:8872455</idno>
<idno type="pmid">8872455</idno>
<idno type="wicri:Area/PubMed/Corpus">002793</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002793</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">The synthesis and biological activities of oligodeoxynucleotides that are covalently linked to psoralen at their 5' ends.</title>
<author>
<name sortKey="Wang, L X" sort="Wang, L X" uniqKey="Wang L" first="L X" last="Wang">L X Wang</name>
<affiliation>
<nlm:affiliation>School of Pharmaceutical Sciences, Beijing Medical University, People's Republic of China.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Yang, D C" sort="Yang, D C" uniqKey="Yang D" first="D C" last="Yang">D C Yang</name>
</author>
<author>
<name sortKey="Lu, Y Y" sort="Lu, Y Y" uniqKey="Lu Y" first="Y Y" last="Lu">Y Y Lu</name>
</author>
<author>
<name sortKey="Takagi, Y" sort="Takagi, Y" uniqKey="Takagi Y" first="Y" last="Takagi">Y. Takagi</name>
</author>
<author>
<name sortKey="Taira, K" sort="Taira, K" uniqKey="Taira K" first="K" last="Taira">K. Taira</name>
</author>
<author>
<name sortKey="Li, T" sort="Li, T" uniqKey="Li T" first="T" last="Li">T. Li</name>
</author>
<author>
<name sortKey="Zhang, L H" sort="Zhang, L H" uniqKey="Zhang L" first="L H" last="Zhang">L H Zhang</name>
</author>
</analytic>
<series>
<title level="j">Drug design and discovery</title>
<idno type="ISSN">1055-9612</idno>
<imprint>
<date when="1995" type="published">1995</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Amino Acid Sequence</term>
<term>Animals</term>
<term>Base Sequence</term>
<term>Cell Division (drug effects)</term>
<term>Ficusin (chemistry)</term>
<term>Ficusin (pharmacology)</term>
<term>Gene Expression (drug effects)</term>
<term>Genes, ras (drug effects)</term>
<term>Mice</term>
<term>Molecular Sequence Data</term>
<term>Oligonucleotides (chemistry)</term>
<term>Oligonucleotides (pharmacology)</term>
<term>Oligonucleotides, Antisense (chemical synthesis)</term>
<term>Oligonucleotides, Antisense (pharmacology)</term>
<term>Proto-Oncogene Proteins p21(ras) (biosynthesis)</term>
<term>Proto-Oncogene Proteins p21(ras) (genetics)</term>
<term>RNA, Messenger (biosynthesis)</term>
<term>Spectrometry, Fluorescence</term>
<term>Spectrophotometry, Ultraviolet</term>
<term>Transfection</term>
<term>Tumor Cells, Cultured</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en">
<term>Proto-Oncogene Proteins p21(ras)</term>
<term>RNA, Messenger</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemical synthesis" xml:lang="en">
<term>Oligonucleotides, Antisense</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en">
<term>Ficusin</term>
<term>Oligonucleotides</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Cell Division</term>
<term>Gene Expression</term>
<term>Genes, ras</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en">
<term>Proto-Oncogene Proteins p21(ras)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Ficusin</term>
<term>Oligonucleotides</term>
<term>Oligonucleotides, Antisense</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Amino Acid Sequence</term>
<term>Animals</term>
<term>Base Sequence</term>
<term>Mice</term>
<term>Molecular Sequence Data</term>
<term>Spectrometry, Fluorescence</term>
<term>Spectrophotometry, Ultraviolet</term>
<term>Transfection</term>
<term>Tumor Cells, Cultured</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Four oligodeoxynucleotides (15-mers), designated 13 through 16, and the corresponding conjugates, designated 17 through 20, in which psoralen was covalently linked to the 5' end of each oligonucleotide were synthesized. Compounds 16 and 20 contained a sequence that was complementary to part of the first four codons and the upstream sequence close to the ribosome-binding site of c-Ha-ras mRNA. Compounds 16 and 20 inhibited the growth of cells that had been transformed by the c-Ha-ras plasmid, with accompanying suppression of the expression of the activated c-Ha-ras oncogene. The antisense oligonucleotides 16 and 20 also appeared to cause partial reversion of the major phenotypic characteristics of transformed cells, which included inhibition of anchorage-independent growth. Compound 20, which contained psoralen, was a more efficient inhibitor of the growth of transformed cells than compound 16 without psoralen, a result that suggests psoralen might have increased the ability of the oligodeoxynucleotides to enter the cells.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">8872455</PMID>
<DateCompleted>
<Year>1997</Year>
<Month>01</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1055-9612</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>13</Volume>
<Issue>2</Issue>
<PubDate>
<Year>1995</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>Drug design and discovery</Title>
<ISOAbbreviation>Drug Des Discov</ISOAbbreviation>
</Journal>
<ArticleTitle>The synthesis and biological activities of oligodeoxynucleotides that are covalently linked to psoralen at their 5' ends.</ArticleTitle>
<Pagination>
<MedlinePgn>109-21</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Four oligodeoxynucleotides (15-mers), designated 13 through 16, and the corresponding conjugates, designated 17 through 20, in which psoralen was covalently linked to the 5' end of each oligonucleotide were synthesized. Compounds 16 and 20 contained a sequence that was complementary to part of the first four codons and the upstream sequence close to the ribosome-binding site of c-Ha-ras mRNA. Compounds 16 and 20 inhibited the growth of cells that had been transformed by the c-Ha-ras plasmid, with accompanying suppression of the expression of the activated c-Ha-ras oncogene. The antisense oligonucleotides 16 and 20 also appeared to cause partial reversion of the major phenotypic characteristics of transformed cells, which included inhibition of anchorage-independent growth. Compound 20, which contained psoralen, was a more efficient inhibitor of the growth of transformed cells than compound 16 without psoralen, a result that suggests psoralen might have increased the ability of the oligodeoxynucleotides to enter the cells.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>L X</ForeName>
<Initials>LX</Initials>
<AffiliationInfo>
<Affiliation>School of Pharmaceutical Sciences, Beijing Medical University, People's Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>D C</ForeName>
<Initials>DC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lu</LastName>
<ForeName>Y Y</ForeName>
<Initials>YY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Takagi</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Taira</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>L H</ForeName>
<Initials>LH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Switzerland</Country>
<MedlineTA>Drug Des Discov</MedlineTA>
<NlmUniqueID>9200627</NlmUniqueID>
<ISSNLinking>1026-7921</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009841">Oligonucleotides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.5.2</RegistryNumber>
<NameOfSubstance UI="D016283">Proto-Oncogene Proteins p21(ras)</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>KTZ7ZCN2EX</RegistryNumber>
<NameOfSubstance UI="D005363">Ficusin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002455" MajorTopicYN="N">Cell Division</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005363" MajorTopicYN="N">Ficusin</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011905" MajorTopicYN="N">Genes, ras</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D009841" MajorTopicYN="N">Oligonucleotides</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName>
<QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016283" MajorTopicYN="N">Proto-Oncogene Proteins p21(ras)</DescriptorName>
<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D013050" MajorTopicYN="N">Spectrometry, Fluorescence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D013056" MajorTopicYN="N">Spectrophotometry, Ultraviolet</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>1995</Year>
<Month>11</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>1995</Year>
<Month>11</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>1995</Year>
<Month>11</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">8872455</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002793 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002793 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:8872455
   |texte=   The synthesis and biological activities of oligodeoxynucleotides that are covalently linked to psoralen at their 5' ends.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:8872455" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021